Pharmacy news

• Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment

  08-10-2026 12:00 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPharmacists are well positioned to lead revenue cycle management for infused medications because they can follow a dru
  
  Read more

• FDA Finalizes Guidance to Broaden Cancer Trial Eligibility

  15-10-2026 02:00 via pharmacypracticenews.com
  
  By Jennifer KulpaThe FDA has finalized three guidance documents urging sponsors to ease overly restrictive eligibility criteria in cancer clinical trials. The recommendations address performance status, washout periods and concomitant medications, and laboratory values, potentially expanding enrollment to more patients treated in ambulatory settings.Issued in July 2026 by the FDA’s Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for Biologics Evaluation a
  
  Read more

• FDA Approves Hovilpri for Refractory HSV Lesions

  14-10-2026 13:26 via pharmacypracticenews.com
  
  Originally published by our sister publication Infectious Disease Special EditionBy Meaghan Lee CallaghanThe FDA has approved pritelivir (Hovilpri, Asahi Kasei) for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, famciclovir, or valacyclovir in immunocompromised adults.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller;
  
  Read more

• The Backup for Drug Shortages Is Required by Law to Arrive Late

  14-10-2026 13:15 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Dalbir BainsAmerica's backup supply of sterile drugs is required by law to arrive late.Start with the scoreboard. ASHP counted
  
  Read more

• Advertisement

• Medicaid Makes the Case for Food as Medicine

  14-10-2026 04:41 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawMedically tailored meals delivered to high-risk Medicaid members were associated with 31% fewer hospitalizations, 20% fewer emergency department visits, and $3,433 lower total healthcare costs per person, in the largest real-world evaluation of the intervention to date.The cost reductions offset 98% of program costs, and among participants with cardiovascular disease, kidney disease, diabetes, depression, or h
  
  Read more

• Pestle and CriticalPoint Announce Partnership to Connect Compounding Education with Pharmacy Compliance Management

  13-10-2026 18:37 via pharmacypracticenews.com
  Pestle, a pharmacy compliance and compounding workflow software, today announced a partnership with CriticalPoint by TRC Healthcare to connect compounding education with the training and compliance activities pharmacies manage in Pestle. Through the partnership, Pestle clients can purchase CriticalPoint education programs and access relevant courses directly from their Pestle training assignments.The partnership brings together CriticalPoint’s compounding education and Pestle’s tools
  
  Read more

• Solid Tumor Therapeutics: What’s New?

  13-10-2026 03:34 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumHeather Ipema, PharmD, BCPSClinical Associate Professor, Drug Information SpecialistUniversity of Illinois Chicago Retzky College of PharmacySolid tumors are among the most common tumor types, comprising 8 of the top 10 most common cancers in men and women.1 Estimates for 2026 list lung cancer, colorectal cancer, and skin melanoma as the most likely new cancer diagnoses in men, and breast, lung, and colorectal as the most
  
  Read more

• Copay Programs, Coupons And Other Risky MC Maneuvers

  12-10-2026 03:28 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawAs pharmacy benefit managers (PBMs) expand the use of copay accumulators, copay maximizers, alternative funding programs (AFPs), and prescription discount cards, specialty pharmacies are finding themselves caught in benefit designs that shift financial risk while obscuring who ultimately controls access to therapy.These programs are drawing heightened scrutiny as specialty drug spending continues to rise, manu
  
  Read more

• Advertisement

• Combination bnAbs Sustained Viral Suppression in Children After ART Interruption

  11-10-2026 05:20 via pharmacypracticenews.com
  
  Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyCombination broadly neutralizing antibodies (bnAbs) maintained viral suppression for 24 weeks in the first children in Botswana with HIV to receive dual- or triple-bnAb treatment after scheduled antiretroviral (ART) therapy interruption, according to preliminary findings (abstract 152) presented at CROI 2026, in Denver.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em
  
  Read more

• Brief Caregiver Education Boosts TD Evaluation and Diagnosis

  10-10-2026 02:18 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawA single 10- to 15-minute online education
  
  Read more

• FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia

  09-10-2026 14:24 via pharmacypracticenews.com
  
  By PPN StaffThe FDA approved olanzapine as an extended-release injectable suspension (Weltruza, Teva) for the treatment of schizophrenia in adults.With the approval, the drug becomes the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of schizophrenia in adults. It does not require loading doses, oral supplementation, or post-injection monitoring.Extended-release injectable olanzapine “combines proven science and novel formulation
  
  Read more

• FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism

  09-10-2026 13:53 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By PPN StaffThe FDA approved remibrutinib (Rhapsido, N
  
  Read more

• Registry Data Support Treating Mild Tardive Dyskinesia

  09-10-2026 02:16 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPatients whose tardive dyskinesia (TD) rate
  
  Read more

• In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s

  08-10-2026 12:00 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawAfter Beth Israel Lahey Health (BILH) brought its employee prescription benefit in-house and began requiring employee
  
  Read more

• Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests

  08-10-2026 03:14 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawNearly one-fourth of patients with tardive
  
  Read more

• FDA Approves Degevma, Biosimilar to Xgeva

  07-10-2026 15:02 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved the biosimilar Degevma (denosumab-adet, Teva) for all indications of its reference product, Xgeva (denosumab, Amgen). These include:• preventing bone complications in adults with advanced cancer that has spread to the bone;• treating adults and skeletally mature adolescents with giant cell tumor of bone; and• treating hypercalcemia of malignancy.Degevma is Teva’s second bi
  
  Read more

• Financial Success Hinges on Proactive Enterprise Planning

  07-10-2026 11:00 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }McMahon Group.By Gina ShawHealth systems are looking to pharmacy to strengthen their finances, but many lack tools to track 340B performance or dedic
  
  Read more

• AAM Report: Generics and Biosimilars Saved $496 Billion in 2025

  06-10-2026 04:45 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzGeneric and biosimilar drugs jointly created $496 billion in savings in 2025 for the U.S. healthcare system and for patients, according to a new report released by the Association for Accessible Medicines and the Biosimilars Council. Savings over the last decade were $3.5 trillion.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure im
  
  Read more

• Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy

  05-10-2026 03:30 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumKristen Whelchel, PharmD, CSPProgram Director, Patient Care ImprovementBrooke Looney, PharmD, CSPClinical Specialty PharmacistStephanie White, PharmD, CSPClinical Specialty PharmacistAutumn D. Zuckerman, PharmD, BCPS, CSPDirector, Health Outcomes and ResearchVanderbilt Specialty PharmacyVanderbilt HealthNashville, TennesseeThe growing use of oral anticancer medications (OAMs) has enabled many patients to receive effective
  
  Read more

• Closing the Rx Gap Between Oncology Guidelines and Practice

  04-10-2026 03:30 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksPersonalized oncology care depends on timely biomarker and genetic testing to guide treatment, but those tests are not always performed when patients need them, speakers said at Asembia’s AXS26 Summit, in Las Vegas. For specialty pharmacists, that gap represents both a patient-care challenge and a call to action: Help identify access barriers, reinforce appropriate testing and treatment pathways, a
  
  Read more

• The Ongoing Struggle of Sickle Cell Disease

  03-10-2026 02:30 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumPatients with sickle cell disease (SCD) still face challenges with pain and fatigue as well as gaining access to a new gene therapy, according to two new studies.The first study found that acute pain and fatigue experienced by people with SCD are associated with higher costs and healthcare resource utilization—to the tune of an additional $7,689 higher per patient per year over counterparts who don&rsqu
  
  Read more

• AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models

  02-10-2026 04:18 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzThe American Hospital Association (AHA) submitted comments on Sept. 23 regarding the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act). The bill was introduced in July and, if passed, would make significant statutory changes to the 340B Drug Pricing Program.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-si
  
  Read more

• FDA Approves Juvmo for Parkinson’s Disease

  01-10-2026 09:27 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved tavapadon (Juvmo, AbbVie) tablets for adults with Parkinson’s disease. The drug is the first selective D1/D5 receptor agonist approved for the disease.The approval was based on data from the TEMPO-3 trial (ClinicalTrials.gov Identifer: NCT04542499) published in JAMA Neurology (2026;83;[5]:442-451).“Development of motor fluctuations is common in people with [Parkinson’s diseas
  
  Read more

• What You Should Know About This Hep C Pipeline Drug

  30-09-2026 11:34 via pharmacypracticenews.com
  
  By Meaghan Lee CallaghanA new investigational drug for the treatment of hepatitis C could one day give clinicians an option that has fewer drug–drug interactions and only an eight-week treatment duration.Janet Hammond, MD, PhD, the chief development officer at Atea Pharmaceuticals, in Boston, sat down with Infectious Disease Special Edition to talk about their new drug in development, a combination of bemnifosbuvir and ruzasvir. Recent research presented at EASL 2026 (poster FRI-635)
  
  Read more

• FDA Approves Ustekinumab for Children With IBD

  29-09-2026 11:26 via pharmacypracticenews.com
  
  Originally published by our sister publication Gastroenterology & Endoscopy NewsBy Katie PrinceThe FDA has approved ustekinumab (Stelara, Johnson & Johnson) for the treatment of children as young as 2 years of age with moderate to severe ulcerative colitis.Ustekinumab, which was approved to treat moderate to severe Crohn’s disease in this population in April, is the first biologic non–tumor necrosis factor inhibitor approved for pediatric patients with inflammatory bowel dise
  
  Read more

• Amneal Announces FDA Approval and Launch of Lanreotide Injection

  28-09-2026 19:21 via pharmacypracticenews.com
  Amneal Pharmaceuticals, Inc. announced that the FDA has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA.“The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines business,” said Srinivas Kone, PhD, senior vice president and chief scientific o
  
  Read more

• Germfree Expands IV Pharmacy Capabilities through Certified Integration of Smarthood with Wolters Kluwer Simplifi+ IV Workflow

  28-09-2026 19:14 via pharmacypracticenews.com
  Germfree Laboratories, LLC, a pioneering leader in modular and mobile cleanroom infrastructure, announced the certified integration of its Smarthood™ sterile compounding hood with Wolters Kluwer Health’s Simplifi+® IV Workflow Management with Assure-Trak® and Simplifi 797® solutions. The integration includes full hardware and software compatibility for highly accurate measurements with both volumetric and gravimetric workflows, allowing pharmacy teams to complete required
  
  Read more

• Genomic Test Identifies Breast Cancer Patients With Minimal Benefit From Chemotherapy

  28-09-2026 11:21 via pharmacypracticenews.com
  
  Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaUse of a 50-gene genomic test identified patients with high-clinical-risk, estrogen receptor–positive (ER+), HER2-negative early breast cancer who could safely avoid chemotherapy without increasing their risk for relapse or death, according to findings from the phase 3 OPTIMA trial.Trial DesignFor OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), the investigat
  
  Read more

• Selpercatinib Receives Traditional Approval for RET Fusion–Positive Solid Tumors

  27-09-2026 11:22 via pharmacypracticenews.com
  
  Originally published by our sister publication Clinical Oncology NewsBy Natasha Albaneze, MPHSelpercatinib (Retevmo, Lilly) was granted approval by the FDA to treat locally advanced or metastatic RET fusion–positive solid tumors in patients at least 2 years of age who have received prior systemic treatment.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:blo
  
  Read more

• New Teva Resource Aims to Move LAIs Earlier in Schizophrenia Care

  25-09-2026 16:12 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }liaksandr Marko, alexkoral - stock.adobe.comBy Gina ShawTeva has launched
  
  Read more

Follow @newsl_pharmacy on Twitter!